M A Carducci

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
    Michael A Carducci
    Division of Medical Oncology, Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 24:4092-9. 2006
  2. ncbi Targeting bone metastasis in prostate cancer with endothelin receptor antagonists
    Michael A Carducci
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 12:6296s-6300s. 2006
  3. ncbi Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
    Wells A Messersmith
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, CRB 1M88, 1650 Orleans Street, Baltimore, MD 21231, USA
    Eur J Cancer 43:78-86. 2007
  4. ncbi Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Dana Rathkopf
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2959-65. 2008
  5. ncbi Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence
    Shabana Shabbeer
    Prostate Cancer Program, 1650 Orleans Street Room 1M59, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231
    Cancer Prev Res (Phila) 5:229-39. 2012
  6. ncbi A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
    Robert S DiPaola
    Department of Medicine, The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick NJ, USA
    J Transl Med 8:20. 2010
  7. ncbi A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
    Lee P Resta
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M59, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 67:431-8. 2011
  8. ncbi Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics
    Michael A Carducci
    Division of Medical Oncology, The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 20:2171-80. 2002
  9. ncbi A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule
    M A Carducci
    Division of Medical Oncology, The Johns Hopkins Oncology Center, 1 M88 Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Clin Cancer Res 7:3047-55. 2001
  10. ncbi A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
    Michael A Carducci
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer 110:1959-66. 2007

Research Grants

  1. Phase I Clinical Trials of New Anti-Cancer Targeted Ther
    Michael Carducci; Fiscal Year: 2007

Collaborators

Detail Information

Publications99

  1. ncbi Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
    Michael A Carducci
    Division of Medical Oncology, Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 24:4092-9. 2006
    ..Enzastaurin is well tolerated up to 700 mg/d. Evidence of early activity was seen with significant stable disease...
  2. ncbi Targeting bone metastasis in prostate cancer with endothelin receptor antagonists
    Michael A Carducci
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 12:6296s-6300s. 2006
    ..Further studies of atrasentan and other selective ET-1 antagonists (ZD4054) are ongoing...
  3. ncbi Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
    Wells A Messersmith
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, CRB 1M88, 1650 Orleans Street, Baltimore, MD 21231, USA
    Eur J Cancer 43:78-86. 2007
    ..A long half-life and accumulation of BPU and active metabolites were observed, recommending against a continuous administration. Weekly oral BPU therapy should be further tested using an interrupted schedule...
  4. ncbi Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Dana Rathkopf
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2959-65. 2008
    ..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers...
  5. ncbi Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence
    Shabana Shabbeer
    Prostate Cancer Program, 1650 Orleans Street Room 1M59, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231
    Cancer Prev Res (Phila) 5:229-39. 2012
    ..When fed before the onset of cancer, that is, in utero, excess methyl donors can have a protective effect on the progression of cancer. Cancer Prev Res; 5(2); 229-39. ©2011 AACR...
  6. ncbi A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
    Robert S DiPaola
    Department of Medicine, The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick NJ, USA
    J Transl Med 8:20. 2010
    ....
  7. ncbi A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
    Lee P Resta
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M59, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 67:431-8. 2011
    ..To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors...
  8. ncbi Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics
    Michael A Carducci
    Division of Medical Oncology, The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 20:2171-80. 2002
    ..Atrasentan, an endothelin antagonist, binds selectively to the ET(A) receptor. This study evaluated the safety, pharmacokinetics, and maximum-tolerated dose of atrasentan in cancer patients...
  9. ncbi A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule
    M A Carducci
    Division of Medical Oncology, The Johns Hopkins Oncology Center, 1 M88 Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Clin Cancer Res 7:3047-55. 2001
    ..We conducted a Phase I and pharmacokinetic study of PB by continuous infusion to characterize the maximum tolerated dose, toxicities, pharmacokinetics, and antitumor effects in patients with refractory solid tumors...
  10. ncbi A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
    Michael A Carducci
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer 110:1959-66. 2007
    ..The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin-A receptor antagonist, in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  11. ncbi Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials
    Michael A Carducci
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland 21231 1000, USA
    Urology 65:18-22; discussion 22. 2005
    ..Patients with high-risk recurrent or metastatic disease should be informed of clinical trials for which they may be eligible...
  12. ncbi A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
    J Gilbert
    Division of Medical Oncology, Department of Oncology, The Johns Hopkins University School of Medicine, 1 M88 Bunting-Blaustein Cancer Research Building, 2650 Orleans Street, Baltimore, MD 21231-1000, USA
    Clin Cancer Res 7:2292-300. 2001
    ..PB may have a role as a cytostatic agent and should be additionally explored in combination with cytotoxics and other novel drugs...
  13. ncbi Novel therapeutic approaches to advanced prostate cancer
    Andrew J Armstrong
    Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 3:271-82. 2005
    ..Clinical advances in meaningful endpoints such as survival and quality of life are eagerly awaited in large-scale trials of active and rationally designed agents...
  14. ncbi Endothelin receptor antagonists in the treatment of prostate cancer
    Lance K Lassiter
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Semin Oncol 30:678-88. 2003
    ....
  15. ncbi Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
    M A Carducci
    The Johns Hopkins Oncology Center and The Brady Urological Institute, Baltimore, Maryland 21205, USA
    Clin Cancer Res 2:379-87. 1996
    ..These results demonstrate that PB induces cytotoxicity via apoptosis in human prostate cancer, in addition to its differentiating properties...
  16. ncbi Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action
    Mario A Eisenberger
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21231 1000, USA
    Urology 63:114-9. 2004
    ..To study the safety, pharmacokinetics, biologic activity, and preliminary efficacy of the bispecific 5-alpha-reductase inhibitor (LY320236) in prostate cancer...
  17. ncbi Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
    R Pili
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 Room 1M52, Baltimore, MD 21231, USA
    Br J Cancer 106:77-84. 2012
    ....
  18. ncbi Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan
    Joel B Nelson
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Urol 169:1143-9. 2003
    ..CONCLUSIONS: Atrasentan suppressed markers of biochemical and clinical prostate cancer progression in bone and demonstrates clinical activity for hormone refractory prostate cancer...
  19. ncbi Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy
    Gopal K Bajaj
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Urology 69:526-31. 2007
    ..This Phase II study was undertaken to determine the safety and efficacy of imatinib mesylate in men with biochemical relapse of nonmetastatic, androgen-sensitive prostate cancer after local therapy...
  20. ncbi Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate
    Janet R Walczak
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000, USA
    Urology 62:141-6. 2003
    ....
  21. ncbi Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors
    E I Heath
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 48:269-74. 2001
    ..The purpose of this trial was to define the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety profile, pharmacokinetics and pharmacodynamics of orally administered BAY12-9566 in patients with incurable solid tumors...
  22. ncbi Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
    J W Simons
    Johns Hopkins Oncology Center, Brady Urological Institute, and Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 59:5160-8. 1999
    ..No antibodies against prostate-specific antigen were detected. These data suggest that both T-cell and B-cell immune responses to human PCA can be generated by treatment with irradiated, GM-CSF gene-transduced PCA vaccines...
  23. ncbi Prostate cancer: a practical approach to current management of recurrent disease
    Janet R Walczak
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
    Mayo Clin Proc 82:243-9. 2007
    ....
  24. ncbi Early use of chemotherapy in conjunction with radical prostatectomy
    Joshi J Alumkal
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-1000, USA
    Clin Prostate Cancer 3:144-9. 2004
    ..Although data for this study are not yet mature, these differences in clinical trial design make such studies in adjuvant chemotherapy for patients with high-risk prostate cancer novel and promising...
  25. ncbi New drugs in prostate cancer
    Andrew J Armstrong
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Curr Opin Urol 16:138-45. 2006
    ..Novel translational clinical trial methodologies may assist in a more rapid identification of active compounds at biologically active doses for phase-III testing...
  26. ncbi Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges
    Eli Rosenbaum
    Division of Medical Oncology, Room 1M-89, Cancer Research Building, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street Baltimore, Maryland 21231, MD 410-502-9746, USA
    Expert Opin Pharmacother 4:875-87. 2003
    ....
  27. ncbi Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:4986-93. 2009
    ..We conducted a randomized, double-blind trial to examine the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy...
  28. ncbi Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy
    M Braga-Basaria
    Department of Medicine, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Bayview Medical Center, Baltimore, MD 21224, USA
    Int J Impot Res 18:494-8. 2006
    ..Long-term prospective studies are needed to determine the time of onset of changes in these lipoproteins while on ADT and the influence of these changes on cardiovascular mortality...
  29. ncbi A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors
    Jianqing Lin
    Chemical Therapeutics Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Clin Cancer Res 15:6241-9. 2009
    ..The pharmacokinetics, pharmacodynamics, and antineoplastic effects were also studied...
  30. ncbi Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects
    Emmanuel S Antonarakis
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, CRB1 191, Baltimore, MD 21231, USA
    Expert Opin Investig Drugs 19:311-4. 2010
    ..These studies provide a rationale for designing clinical trials that combine low-dose cyclophosphamide with GM-CSF-secreting cell-based immunotherapy in patients with prostate and other cancers...
  31. ncbi Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors
    Wells A Messersmith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:1270-5. 2006
    ..Preclinical studies have shown synergy between bortezomib and taxanes. We conducted a phase I study combining bortezomib and docetaxel in refractory solid tumor patients...
  32. ncbi Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy
    Shehzad Basaria
    Department of Medicine, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, and National Institut on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA
    Cancer 106:581-8. 2006
    ....
  33. ncbi Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor
    Sushant K Kachhap
    Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 5:e11208. 2010
    ..The mechanism behind this downregulation remains unclear. Here we provide evidence that several DNA repair genes are downregulated by HDAC inhibition and provide a mechanism involving the E2F1 transcription factor in the process...
  34. ncbi Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial
    Eli Rosenbaum
    Department of Radiation Oncology and Molecular Sciences, Division of Medical Oncology and Biostatistics and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 11:4437-43. 2005
    ..Confirmatory studies with less toxic matrix metalloproteinase inhibitors employing more conventional end points are indicated. This design is feasible and potentially efficient for screening antimetastatic agents...
  35. ncbi Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma
    Victoria J Sinibaldi
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Clin Oncol 29:395-8. 2006
    ....
  36. ncbi Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy
    Milena Braga-Basaria
    Department of Medicine, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Bayview Medical Center, Baltimore, MD 21224, USA
    J Clin Oncol 24:3979-83. 2006
    ..Because male hypogonadism is a risk factor for metabolic syndrome and men with PCa have high cardiovascular mortality, we evaluated the prevalence of metabolic syndrome in men undergoing long-term ADT...
  37. ncbi Novel targeted therapeutics for metastatic castration-resistant prostate cancer
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, United States
    Cancer Lett 291:1-13. 2010
    ....
  38. ncbi Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building, Room 544, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:1119-27. 2008
    ..To assess the pharmacogenomic and pharmacokinetic determinants of skin rash and diarrhea, the two primary dose-limiting toxicities of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib...
  39. ncbi Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs
    Henk M W Verheul
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Cancer Research Building, 1M52, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 60:329-39. 2007
    ..In this report we explored the hypotheses that these "cytostatic" agents may have a greater antitumor activity in combination with "cytotoxic" compounds and their biological effect may be sequence-dependent...
  40. ncbi The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy
    Danil V Makarov
    James Buchanan Brady Urological Institute and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 179:156-61; discussion 161-2. 2008
    ....
  41. ncbi Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Cancer Research Building I, Baltimore, MD, USA
    Cancer Chemother Pharmacol 61:423-33. 2008
    ....
  42. ncbi The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin
    Sushant K Kachhap
    Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 2:e844. 2007
    ..This novel finding of NDRG1 as a recycling protein involved with recycling of E-cadherin will aid in understanding NDRG1 role as a metastasis suppressor protein...
  43. ncbi Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 23:3906-11. 2005
    ..To characterize the pharmacokinetic behavior of 5-azacitidine (5-AC), a cytidine nucleoside analog, when given with phenylbutyrate, a histone deaceytlase inhibitor...
  44. ncbi Differentiation therapy
    Alexander I Spira
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB Room 1M89, Baltimore, MD 21231, USA
    Curr Opin Pharmacol 3:338-43. 2003
    ..Many agents have been studied over the past few years, with many already either in use clinically or showing future promise...
  45. ncbi Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial
    Michael A Carducci
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    J Clin Oncol 21:679-89. 2003
    ..Quality of life was not adversely affected by atrasentan. CONCLUSION: Atrasentan is an oral, targeted therapy with favorable tolerability and the potential to delay progression of HRPCa...
  46. ncbi Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Anal Biochem 324:276-84. 2004
    ....
  47. ncbi The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate
    Elisabeth I Heath
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Prostate Cancer 1:182-7. 2002
  48. ncbi Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:1976-83. 2004
    ..The comparative pharmacokinetics of docetaxel during weekly and once every 3 weeks (3-weekly) administration schedules were evaluated...
  49. ncbi Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma
    Victoria J Sinibaldi
    Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer 94:1457-65. 2002
    ..To preserve the therapeutic synergism between docetaxel and EMP, they designed a regimen employing higher doses of oral EMP administered on the day of the docetaxel infusion...
  50. ncbi Factors affecting cytochrome P-450 3A activity in cancer patients
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:8341-50. 2004
    ..The purpose is to identify the demographic, physiologic, and inheritable factors that influence CYP3A activity in cancer patients...
  51. ncbi A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors
    E Claire Dees
    Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
    Clin Cancer Res 11:664-71. 2005
  52. ncbi Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21230 1000, USA
    Clin Cancer Res 9:3589-97. 2003
    ..This Phase I trial examined its toxicity and pharmacokinetics (PKs)...
  53. ncbi Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies
    Andrew J Armstrong
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, CRB 1M88, 1650 Orleans Street, Baltimore, MD 21231, USA
    Curr Oncol Rep 7:220-7. 2005
    ..The role of chemotherapy for advanced disease in the neoadjuvant or adjuvant setting, in biochemically (PSA) relapsed patients, and as second-line therapy for relapsed disease, remains a subject of active clinical investigation...
  54. ncbi Future directions in castrate-resistant prostate cancer therapy
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Genitourin Cancer 8:37-46. 2010
    ..The future of CRPC therapy appears brighter than ever before...
  55. ncbi Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis
    R Pili
    The Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA
    Cancer Res 61:1477-85. 2001
    ..004 versus single agents). In summary, this study showed an additive inhibitory effect of combination of differentiation agents PB and CRA on prostate tumor growth through a direct effect on both tumor and endothelial cells...
  56. ncbi A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010
    ..Although sorafenib showed only modest clinical activity as a single agent in this heavily treated population, robust inhibition of FLT3 and ERK suggests that there may be a potential important role in combination therapies...
  57. ncbi Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
    S D Gore
    The Johns Hopkins Oncology Center, Room 288, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Expert Opin Investig Drugs 9:2923-34. 2000
    ....
  58. ncbi Fenugreek: a naturally occurring edible spice as an anticancer agent
    Shabana Shabbeer
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Cancer Biol Ther 8:272-8. 2009
    ..Thus, these studies add another biologically active agent to our armamentarium of naturally occurring agents with therapeutic potential...
  59. ncbi A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors
    Madeleine S Q Kortenhorst
    Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Cancer Res 14:6886-94. 2008
    ..In this article, we present our experience with a complex design microarray experiment on resistance mechanisms of histone deacetylase inhibitors (HDACI)...
  60. ncbi Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint
    Connie Collins
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Biol Ther 6:1360-7. 2007
    ..CEP-701 binds to serum proteins and a preprostatectomy study was performed to assess prostate tissue penetration and clinical response to CEP-701...
  61. ncbi Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
    W G Nelson
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 46:S67-72. 2000
    ....
  62. ncbi Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 19:837-45. 2010
    ..We explored using needs assessments to identify HRQOL scores associated with patient-reported unmet needs...
  63. ncbi Palliative chemotherapy: historical perspective, applications, and controversies
    Ilene Browner
    Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD 21231-2410, USA
    Semin Oncol 32:145-55. 2005
    ....
  64. ncbi Relevant content for a patient-reported outcomes questionnaire for use in oncology clinical practice: Putting doctors and patients on the same page
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 19:1045-55. 2010
    ..To investigate relevant patient-reported outcome (PRO) domains for oncology clinical practice...
  65. ncbi Advanced prostate cancer: the future
    Andrew J Armstrong
    Prostate Cancer Research Program, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Can J Urol 12:42-7. 2005
    ..Novel approaches including novel cytotoxics, immunotherapy, PSMA targeted monoclonal antibodies are among the broad categories that will be discussed in this brief review...
  66. ncbi Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography
    Ming Zhao
    Division of Experimental Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M87, Baltimore, MD 21231, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 813:81-8. 2004
    ..This method is 50 times more sensitive than previously published assays and successfully allows studies to characterize the pharmacokinetics and pharmacodynamics of 5AC...
  67. ncbi A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma
    Usha Sunkara
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-1000, USA
    J Interferon Cytokine Res 24:37-41. 2004
    ..The combination of TEM/IFN proved quite tolerable. This regimen appears inactive in terms of response in this population with poor prognosis, but the patients with stable disease > or =6 months remain of interest...
  68. ncbi Does pre-existing diabetes affect prostate cancer prognosis? A systematic review
    C F Snyder
    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Prostate Cancer Prostatic Dis 13:58-64. 2010
    ..20). Diabetes was also associated with receiving radiation therapy, complication rates, recurrence and treatment failure. Our analysis suggests that pre-existing diabetes affects the treatment and outcomes of men with prostate cancer...
  69. ncbi A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
    T L DeWeese
    Division of Radiation Oncology, The Johns Hopkins Oncology Center, Baltimore, Maryland 21231-1000, USA
    Cancer Res 61:7464-72. 2001
    ....
  70. ncbi Symptoms, supportive care needs, and function in cancer patients: how are they related?
    Claire F Snyder
    Johns Hopkins School of Medicine, Baltimore, MD, USA
    Qual Life Res 17:665-77. 2008
    ..To explore the associations among symptoms, supportive care needs, and function...
  71. ncbi Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo
    Madeleine S Q Kortenhorst
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, James Buchanan Brady Urological Institute, School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Mol Cancer Ther 8:802-8. 2009
    ..Therefore, nuclear structural alterations may serve as a biomarker for histone deacetylase inhibitor treatment...
  72. ncbi Endothelin-1 as a target for therapeutic intervention in prostate cancer
    E Scott Kopetz
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Invest New Drugs 20:173-82. 2002
    ..Results of ongoing clinical trials are eagerly awaited in order to see if the hypothetical promise of ET antagonism will result in clinical success...
  73. ncbi Concordance of cancer patients' function, symptoms, and supportive care needs
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 18:991-8. 2009
    ..Although patients' function, symptoms, and supportive care needs are obviously related, a better understanding of these relationships could improve patient management...
  74. ncbi Pharmacological treatments for prostate cancer
    Janet R Walczak
    Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins, Department of Nursing, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Expert Opin Investig Drugs 11:1737-48. 2002
    ....
  75. ncbi Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice
    Claire F Snyder
    Division of General Internal Medicine, Johns Hopkins School of Medicine, 624 N Broadway, 6th Floor, Baltimore, MD 21205, USA
    Support Care Cancer 15:1075-85. 2007
    ..We investigated the item content from two health-related quality-of-life (HRQOL) questionnaires and two needs assessments for this purpose...
  76. ncbi Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo
    Shabana Shabbeer
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland 21231, USA
    Prostate 67:1099-110. 2007
    ..It is a known Histone Deacetylase Inhibitor (HDACI). We tested VPA, for its anti-proliferative activity in prostate cancer (PCa) cell lines in vitro and in vivo...
  77. ncbi Focus on deacetylation for therapeutic benefit
    Shabana Shabbeer
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    IDrugs 8:144-54. 2005
    ..This review focuses on the cellular and biological effects of HDACIs, either alone or in combination with other agents. A brief summary on completed and ongoing cancer clinical trials is provided...
  78. ncbi A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation
    Kuo-Shyan Lin
    Department of Environmental Health Sciences, The Johns Hopkins Medical Institutions, 615 North Wolfe Street, Baltimore, Maryland 21205, USA
    Bioconjug Chem 16:43-50. 2005
    ..Scintigraphic images showed specific, high contrast delineation of prostate cancer PC-3 xenografts in SCID mice. Thus, the new peptide has a great potential for imaging BN/GRP receptor-positive cancers located even in the abdomen...
  79. ncbi Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha
    David Z Qian
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Cancer Res 66:8814-21. 2006
    ..Taken together, these results suggest that class II HDACs are associated with HIF-1 alpha stability and provide a rationale for targeting HIF-1 alpha with HDAC inhibitors against class II isozymes...
  80. ncbi HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides
    J Lin
    Jefferson Kimmel Cancer Center, 834 Chestnut Street, Suite 314, Philadelphia, PA 19107, USA
    Curr Cancer Drug Targets 9:881-7. 2009
    ..The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed...
  81. ncbi A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
    Jill Gilbert
    Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA
    Invest New Drugs 24:499-508. 2006
    ..This was correlated with higher CNDAC Cmax and AUC values. No tumor responses were noted in this heavily pretreated population. However, given the ease of administration and tolerability, further investigation of this agent is warranted...
  82. ncbi Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly
    Albert J ten Tije
    Erasmus University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 23:1070-7. 2005
    ..091). CONCLUSION: Docetaxel plasma pharmacokinetics are unaltered in elderly patients. Patients aged >/= 65 years appear to be more sensitive to docetaxel-induced neutropenia...
  83. ncbi A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer
    Eric J Small
    University of California, Comprehensive Cancer Center San Francisco, San Francisco, CA 94143, USA
    Mol Ther 14:107-17. 2006
    ..No partial or complete prostate-specific antigen (PSA) responses were observed; however, 5 patients had a decrease in serum PSA of 25% to 49% following a single treatment, including 3 of 8 patients at the highest dose levels...
  84. ncbi What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer?
    Michael A Carducci
    J Clin Oncol 23:3304-7. 2005
  85. ncbi Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study
    Surasak Phuphanich
    The New Approaches to Brain Tumor Therapy CNS Consortium, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Neuro Oncol 7:177-82. 2005
    ..The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants...
  86. ncbi Docetaxel in androgen-independent prostate cancer: an update
    Masood A Khan
    Department of Urology, St. Bartholomew's Hospital, London, UK
    BJU Int 94:1209-10. 2004
  87. ncbi Recommendations for defining and treating high risk localized prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Urol 176:S6-S10; quiz S3-5. 2006
  88. ncbi American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer
    Ethan M Basch
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:5313-8. 2007
    ..The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer...
  89. ncbi Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer
    Jonathan W Simons
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 12:3394-401. 2006
    ....
  90. ncbi Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:537-56. 2004
    ..To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA)...
  91. ncbi Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
    Lillian L Siu
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Ste 5 718, Toronto, Ontario, M5G 2M9, Canada
    J Clin Oncol 26:1940-7. 2008
    ..MGCD0103 is a novel isotype-selective inhibitor of human histone deaceylases (HDACs) with the potential to regulate aberrant gene expression and restore normal growth control in malignancies...
  92. ncbi Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
    Andrew J Armstrong
    Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    J Clin Oncol 25:3965-70. 2007
    ..Here we examined various degrees of PSA decline and pain response as surrogates for the survival benefit observed in the TAX327 trial...
  93. ncbi Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy
    Lance K Lassiter
    Matthews Hematology Oncology Associates, Matthews, NC, USA
    Clin Genitourin Cancer 6:31-5. 2008
    ..We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial carcinoma and who proved nonresponsive to standard chemotherapy...
  94. ncbi Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay
    Claire Bonfils
    MethylGene, Inc, Montreal, Quebec, Canada
    Clin Cancer Res 14:3441-9. 2008
    ..The pharmacodynamic properties of MGCD0103, an isotype-selective inhibitor of histone deacetylase (HDAC), were evaluated in preclinical models and patients with a novel whole-cell HDAC enzyme assay...
  95. ncbi Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer
    Shehzad Basaria
    Arch Intern Med 167:612-3. 2007
  96. ncbi Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    J Clin Oncol 25:669-74. 2007
    ..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel...
  97. ncbi A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer
    Donald S Kaufman
    Massachusetts General Hospital, Boston, MA, USA
    Urol Oncol 22:393-7. 2004
    ..Insufficient patients with poor renal function or prior therapy were accrued to reach conclusions regarding its utility in these subgroups...
  98. ncbi Testicular cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1038-58. 2006
  99. ncbi Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...

Research Grants2

  1. Phase I Clinical Trials of New Anti-Cancer Targeted Ther
    Michael Carducci; Fiscal Year: 2007
    ..We expect to enroll 50-60 patients/year in order to conduct and complete 2-3 phase I clinical trials/year via this cooperative agreement. ..